PTK2 and breast cancer: Since FAK is activated by many binding partners and interconnected with different pathways, combinatorial therapies using FAK inhibitors along with compounds halting key signaling mediators and adaptive resistance mechanisms may represent a promising therapeutic strategy in diverse tumors, including breast cancer [226].